Skip to main content

Table 1 Baseline characteristics of patients between first-week iron and third-week iron groups

From: Timing-adjusted iron dosing enhances erythropoiesis-stimulating agent-induced erythropoiesis response and iron utilization

Variables First-week iron group Third-week iron group P value
n = 51 n = 53
Age, years 67.8 ± 10.2 67.6 ± 11.6 0.919
Male, % 60.8 52.8 0.413
Body mass index, kg/m2 21.9 ± 3.6 21.8 ± 3.2 0.815
Hemodialysis vintage, months 94.7 ± 89.0 108.0 ± 75.5 0.158
Single-pool Kt/V 1.05 ± 0.20 1.12 ± 0.24 0.113
Mean CERA dose, μg/4 weeks 129.6 ± 66.9 117.9 ± 68.2 0.344
Arteriovenous fistula, % 96.1 98.1 0.465
Renin-angiotensin system inhibitors, % 49.0 58.5 0.333
Diabetes mellitus, % 35.3 41.5 0.515
Hypertension, % 96.1 98.1 0.485
Cardio vascular disease, % 25.5 24.5 0.910
Hematologic disease, % 5.9 1.9 0.294
Hemoglobin, g/dl 10.7 ± 0.7 10.8 ± 0.9 0.767
Creatinin, mg/dl 11.0 ± 2.2 1.0 ± 2.5 0.906
Blood urea nitrogen, mg/dl 71.6 ± 17.1 72.3 ± 14.6 0.844
Albumin, g/dl 3.85 ± 0.22 3.85 ± 0.31 0.969
C-reactive protein, mg/dl 0.32 ± 0.54 0.22 ± 0.34 0.865
Intact-parathyroid hormon, pg/ml 164.7 ± 78.8 180.1 ± 108.2 0.797
Serum iron, μg/dl 96.4 ± 30.1 89.6 ± 25.9 0.248
Total Iron binding capacity, μg/dl 236.7 ± 34.1 237.1 ± 42.7 0.955
Transferrin saturation, % 40.9 ± 14.2 40.2 ± 14.8 0.826
Ferritin, ng/ml 163.3 ± 63.7 169.6 ± 63.1 0.623
  1. Data are mean ± SD. P values for the difference between the two groups
  2. CERA continuous erythropoietin receptor activator